×

Stocks Merck & Co Inc

  • BBB_Badge.jpg

    Stocks slipped Friday as weaker consumer sentiment compounded losses after disappointing earnings from American Express, Amazon and Microsoft. The disappointing earnings and sentiment gave investors reason to pause and take a breather after a significant run-up in the past few weeks, in which the Nasdaq logged 12 straight gains — its longest run since 1992. Read and listen to what the experts had to say...

  • Stocks skidded Friday as a drop in consumer sentiment exacerbated losses triggered by a disappointing round of earnings from American Express, Amazon and Microsoft.

  • They’ve come a long way in 12 months. Here’s an up-to-date snapshot of where they are now.

  • A late rally pushed stocks higher Tuesday following better-than-expected earnings from several Dow components. The Dow logged its seventh-straight gain, the Nasdaq, it's tenth.

  • The Mad Money host makes the call on a few key blue-chip companies and more.

  • The Dow advanced Tuesday as a slew of components beat earnings expectations. But there were pockets of weakness throughout the market, including chips, hardware, banks and retail. The Nasdaq was lower.

  • The trend continues: earnings beat, but revenues light. But that's good enough: stock futures are popping on the news. Why? Two reasons.

  • Companies as diverse as Caterpillar, Merck and Coca-Cola reported quarterly profit that beat analyst estimates. Does this signify an embryonic bull market at last? Art Cashin, director of floor operations at UBS Financial Services, offered CNBC his stock-market insights.

  • Shingles image from Zostavax.com

    Recently, Merck came out with the first vaccine for shingles called Zostavax. But it had manufacturing and supply issues that hurt the launch. In its earnings press release today, Merck says as of last month it has "resumed normal shipping schedules for Zostavax."

  • U.S. drugmaker Schering-Plough said on Tuesday its second-quarter earnings rose after lower special charges, but global revenue declined as the weak dollar hurt sales in overseas markets.

  • The Dow bolted out of the gate Tuesday as a slew of components beat earnings expectations. But there were pockets of weakness throughout the market, including chips, hardware, banks and retail. The Nasdaq was lower.

  • Futures indicated a slightly lower open for Wall Street Tuesday ahead of a slew of earnings and Federal Reserve Chairman Ben Bernanke's Capitol Hill testimony.

  • Mike Williams of Genesis Asset Management and Douglas Roberts of ChannelCapitalResearch.com shared their investment strategies. (Part One)

  • Sonia Sotomayor, as nominee for US Supreme Court Justice.

    Though Sonia Sotomayor is widely expected to win confirmation to the US Supreme Court, the business community is still wondering just what kind of justice she'll be

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • graphic_word_ofthe_street.jpg

    The S&P edged higher on Thursday with investors rotating into beaten down energy names and financials and out of consumer staples and pharma.

  • Stocks squeaked out another gain Thursday as investors were encouraged by Alcoa's beat and a drop in jobless claims but pharmaceutical and retail stocks dragged.

  • A late upturn pushed stocks higher Wednesday as investors rotated into defensive stocks like pharmaceuticals and Alcoa advanced ahead of earnings.

  • Stocks turned lower Wednesday as investors got defensive ahead of earnings season, rotating into pharmaceuticals and out of techs.

  • Perhaps reflecting concerns about the size and growth of the market for HPV shots and GSK's late entry, investors are not enthusiastic about the prestigious publication of the company's robust new test results. As I write this, GSK shares are the biggest percentage loser in big pharma.